|
PGBD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.43152156795168E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88327131667165E-12 |
| Normal-vs-Stage2 |
2.31739999967395E-07 |
| Normal-vs-Stage3 |
1.8810508706224E-12 |
| Normal-vs-Stage4 |
1.8499646259329E-12 |
| Stage1-vs-Stage2 |
1.113440E-01 |
| Stage1-vs-Stage3 |
2.383000E-01 |
| Stage1-vs-Stage4 |
1.678970E-01 |
| Stage2-vs-Stage3 |
3.591800E-02 |
| Stage2-vs-Stage4 |
2.247700E-02 |
| Stage3-vs-Stage4 |
6.714400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.5400792580399E-12 |
| Normal-vs-AfricanAmerican |
2.30969999792663E-08 |
| Normal-vs-Asian |
1.08129949438762E-10 |
| Caucasian-vs-AfricanAmerican |
3.120200E-01 |
| Caucasian-vs-Asian |
7.355000E-01 |
| AfricanAmerican-vs-Asian |
5.356000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.38031816479634E-13 |
| Normal-vs-Female |
3.32844862782622E-12 |
| Male-vs-Female |
1.226970E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.09987624247788E-13 |
| Normal-vs-Age(41-60Yrs) |
7.44504458083384E-12 |
| Normal-vs-Age(61-80Yrs) |
7.93032306489749E-12 |
| Normal-vs-Age(81-100Yrs) |
6.433900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.193200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.431000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.698600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.140800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.453200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.088200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.803100E-03 |
| Classical-VS-Follicular |
2.897200E-01 |
| Classical-VS-Other |
3.685200E-01 |
| Classical-VS-Normal |
9.7604146986896E-12 |
| Tall-VS-Follicular |
2.096500E-03 |
| Tall-VS-Other |
8.588000E-01 |
| Tall-VS-Normal |
3.30846461338297E-14 |
| Follicular-VS-Other |
3.186200E-01 |
| Follicular-VS-Normal |
9.45259981399715E-10 |
| Other-VS-Normal |
5.567900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.41824396250013E-12 |
| Normal-vs-N1 |
1.83197901293397E-12 |
| N0-vs-N1 |
5.670500E-02 |
|
|
